Federal Circuit Affirms in Part, Vacates in Part in Maquet v. Abiomed Intravascular Blood Pump Patent Dispute

Case Overview

The Parties

The Patents at Issue

This landmark case involved six U.S. patents covering intravascular blood pump technology, forming the technological foundation of Maquet’s infringement allegations. These patents collectively cover technologies related to intravascular blood pump design, function, and associated systems.

• • US7022100B1
• • US9561314B2
• • US9597437B2
• • US8888728B2
• • US9327068B2
• • US9545468B2

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a verdict of AFFIRMED-IN-PART, VACATED-IN-PART, AND REMANDED in this intravascular blood pump patent infringement case. This split disposition means the appellate court upheld certain lower-level findings while invalidating or reversing others—and directed the case back to the originating tribunal for further proceedings. Specific damages figures and injunctive relief determinations were not disclosed in the available case data.

Verdict Cause Analysis

The case was categorized as an Infringement Action. An affirmed-in-part, vacated-in-part outcome at the Federal Circuit level is legally significant, indicating the appellate court identified at least one reversible error in the lower proceedings—whether in claim construction, validity analysis, infringement findings, or application of procedural standards—while simultaneously affirming findings on other patents or claims. In multi-patent cases of this nature, such outcomes frequently arise from disputes over how specific claim terms were interpreted, which directly controls the scope of the infringement analysis.

Legal Significance

The Federal Circuit’s decision carries binding precedential weight across all U.S. district courts in patent cases. A mixed affirmance and vacation in a six-patent intravascular device case creates important reference points for how appellate courts evaluate multi-patent infringement records in medical device litigation, the standards applied when vacating lower-level findings involving complex technical claim terms, and the procedural posture of remand instructions in patent cases involving overlapping claim families.

Strategic Takeaways

For Patent Holders: Portfolio-based assertion strategies—asserting multiple related patents—can increase litigation resilience. Even when some claims or patents are vacated, others may be affirmed, preserving leverage. Maquet’s six-patent approach exemplifies this multi-front strategy.

For Accused Infringers: A vacated-in-part result demonstrates the value of targeted appellate challenges. Identifying and isolating specific claim construction errors or evidentiary deficiencies can result in meaningful relief even where full reversal is unachievable.

For R&D Teams: When developing products in crowded patent landscapes—such as cardiac assist devices—freedom-to-operate (FTO) analyses must account for patent families, not just individual patents. The Impella platform’s exposure across six patents underscores the risk of incremental product iteration within a contested technology space.